09:20:54 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Camurus är veksamma inom bioteknik. Bolaget drivs som ett forskningsbaserat läkemedelsbolag och utvecklar samt distribuerar produkter för behandling av svåra och kroniska sjukdomar. Sjukdomar som behandlas med bolagets produkter innefattar exempelvis cancer, endokrina störningar samt patienter med opioidberoende. Camurus driver utvecklingsprojekt i egen regi samt i partnerskap med internationella läkemedelsbolag. Bolaget har sitt säte i Lund.

Kalender

2022-11-10 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning CAMX 0.00 SEK
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-06 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning CAMX 0.00 SEK
2020-05-07 Kvartalsrapport 2020-Q1
2020-05-07 Årsstämma 2020
2020-02-12 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning CAMX 0.00 SEK
2019-05-09 Årsstämma 2019
2019-05-09 Kvartalsrapport 2019-Q1
2019-02-06 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-07-17 Kvartalsrapport 2018-Q2
2018-05-04 Ordinarie utdelning CAMX 0.00 SEK
2018-05-03 Kvartalsrapport 2018-Q1
2018-05-03 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-13 Kvartalsrapport 2017-Q2
2017-05-04 Ordinarie utdelning CAMX 0.00 SEK
2017-05-03 Årsstämma 2017
2017-05-03 Kvartalsrapport 2017-Q1
2017-02-16 Bokslutskommuniké 2016
2016-10-22 Kvartalsrapport 2016-Q3
2016-07-14 Kvartalsrapport 2016-Q2
2016-05-17 Kvartalsrapport 2016-Q1
2016-05-04 Ordinarie utdelning CAMX 0.00 SEK
2016-05-03 Årsstämma 2016
2016-03-30 Bokslutskommuniké 2015
2021-09-16 11:00:00

Lund, Sweden - 16 September 2021 - Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company's investigational medicinal product, octreotide subcutaneous depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease.

Polycystic liver disease (PLD) is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver which can cause severe symptoms and result in an impaired quality of life of patients. There is today no approved pharmacological treatment available for PLD.

"The orphan drug designation for CAM2029 is a significant milestone in our efforts to develop an effective pharmacological treatment for people with polycystic liver disease and a recognition of the importance of our overall development program for CAM2029," says Dr. Fredrik Tiberg, CEO and Head of R&D at Camurus. "CAM2029 is designed to address a significant unmet medical need in this population and could potentially become the first approved pharmacological treatment for PLD in the US market." 

Camurus has also recently received a Safe-to-Proceed letter from the FDA for the start of a randomized placebo-controlled Phase 2/3 study designed to assess efficacy and safety of CAM2029 in patients with symptomatic PLD.

Orphan drug designation qualifies the drug developer for a variety of development incentives and the prospect of seven years of market exclusivity, if approved. The FDA's ODD program is designed to advance the development of drugs for the treatment of rare diseases affecting fewer than 200.000 people in the US. More information about FDA rare diseases and the ODD program is available on www.fda.org (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=836621).

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
 

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
 

About polycystic liver disease
Polycystic liver disease (PLD) is a rare genetic and chronic disorder characterized by progressive growth of multiple (> 10) fluid-filled cysts in the liver, which can cause severe symptoms such as abdominal pain and discomfort, shortness of breath (dyspnea), indigestion (dyspepsia), gastro-esophageal reflux, and limited mobility. Rare complications are hepatic cyst hemorrhage, infection or rupture.[1-3 ]Age and gender contribute to disease severity; increasing age is positively associated with both cyst sizes and numbers, and women are highly overrepresented among symptomatic patients.[4-6] Most patients with PLD are diagnosed in their 30s after reporting a sudden and accelerated increase of abdominal girth, together with other PLD-related symptoms.[5 ]There is currently no approved pharmacological treatment for PLD, but growing scientific evidence has shown that somatostatin analogues, such as octreotide, are effective in slowing cyst growth and fluid secretion in the liver and that they may also help reduce liver volume.[7-9]

About CAM2029
CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide under development for treatment of three rare diseases; acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). CAM2029 has been successfully evaluated in four completed clinical Phase 1 and 2 studies and is being assessed in two ongoing pivotal Phase 3 studies in acromegaly and a pivotal Phase 3 study in GEP-NET. A Phase 2/3 study in patients with PLD is under preparation. CAM2029 is developed for enhanced octreotide exposure and easy self-administration by patients using a prefilled pen injector. CAM2029 has been granted orphan designation in the EU for the treatment of acromegaly and in the US for the treatment of PLD.   

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

References[AB1]

1. Abu-Wasel, B., et al., Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol, 2013. 19(35): p. 5775-86.
2. Perugorria, M.J., et al., Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol, 2014. 11(12): p. 750-61.
3. Neijenhuis, M.K., et al., Impact of liver volume on polycystic liver disease-related symptoms and quality of life. United European Gastroenterol J, 2018. 6(1): p. 81-88.
4. Van Keimpema L., et al. . Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver international : official journal of the International Association for the Study of the Liver. 2011;31(1):92-8.
5. van Aerts RMM, et al. . Clinical management of polycystic liver disease. J Hepatol. 2018;68(4):827-37.50. van Aerts RMM, Kievit W, de Jong ME, Ahn C, Bañales JM, Reiterová J, et al. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. Liver international : official journal of the International Association for the Study of the Liver. 2019;39(3):575-82.
6. Gevers T. J. G., et al. Liver Int. 2015 May;35(5):1607-14.. doi (https://pubmed.ncbi.nlm.nih.gov/25369108/): 10.1111/liv.12726; (https://pubmed.ncbi.nlm.nih.gov/25369108/)
7. isani A., et al. Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030. doi (https://pubmed.ncbi.nlm.nih.gov/26844873/): 10.1016/j.cgh.2015 (https://pubmed.ncbi.nlm.nih.gov/26844873/);
8. van Aerts R., et al., Gastroenterology. 2019 Aug;157(2):481-491. doi:10.1053/j.gastro.2019.04.018 (https://pubmed.ncbi.nlm.nih.gov/31022403/)

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 11:00 am CET on 16 September 2021.